|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BRMS1L |
Gene summary for BRMS1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BRMS1L | Gene ID | 84312 |
| Gene name | BRMS1 like transcriptional repressor | |
| Gene Alias | BRMS1 | |
| Cytomap | 14q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q5PSV4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84312 | BRMS1L | LZE4T | Human | Esophagus | ESCC | 1.48e-03 | 1.60e-01 | 0.0811 |
| 84312 | BRMS1L | LZE24T | Human | Esophagus | ESCC | 8.83e-03 | 7.98e-02 | 0.0596 |
| 84312 | BRMS1L | LZE6T | Human | Esophagus | ESCC | 1.80e-02 | 9.30e-02 | 0.0845 |
| 84312 | BRMS1L | P2T-E | Human | Esophagus | ESCC | 5.30e-14 | 2.58e-01 | 0.1177 |
| 84312 | BRMS1L | P4T-E | Human | Esophagus | ESCC | 1.75e-13 | 2.83e-01 | 0.1323 |
| 84312 | BRMS1L | P5T-E | Human | Esophagus | ESCC | 1.51e-10 | 2.10e-01 | 0.1327 |
| 84312 | BRMS1L | P8T-E | Human | Esophagus | ESCC | 6.77e-31 | 5.64e-01 | 0.0889 |
| 84312 | BRMS1L | P9T-E | Human | Esophagus | ESCC | 4.88e-10 | 1.78e-01 | 0.1131 |
| 84312 | BRMS1L | P10T-E | Human | Esophagus | ESCC | 6.39e-12 | 2.65e-01 | 0.116 |
| 84312 | BRMS1L | P11T-E | Human | Esophagus | ESCC | 2.56e-06 | 2.45e-01 | 0.1426 |
| 84312 | BRMS1L | P12T-E | Human | Esophagus | ESCC | 8.38e-54 | 8.81e-01 | 0.1122 |
| 84312 | BRMS1L | P15T-E | Human | Esophagus | ESCC | 4.05e-18 | 3.38e-01 | 0.1149 |
| 84312 | BRMS1L | P16T-E | Human | Esophagus | ESCC | 5.21e-07 | 1.07e-01 | 0.1153 |
| 84312 | BRMS1L | P17T-E | Human | Esophagus | ESCC | 1.09e-02 | 1.75e-01 | 0.1278 |
| 84312 | BRMS1L | P20T-E | Human | Esophagus | ESCC | 6.05e-09 | 1.46e-01 | 0.1124 |
| 84312 | BRMS1L | P21T-E | Human | Esophagus | ESCC | 4.24e-04 | 9.84e-02 | 0.1617 |
| 84312 | BRMS1L | P22T-E | Human | Esophagus | ESCC | 3.44e-09 | 1.19e-01 | 0.1236 |
| 84312 | BRMS1L | P23T-E | Human | Esophagus | ESCC | 2.29e-11 | 3.32e-01 | 0.108 |
| 84312 | BRMS1L | P24T-E | Human | Esophagus | ESCC | 6.37e-09 | 2.28e-01 | 0.1287 |
| 84312 | BRMS1L | P26T-E | Human | Esophagus | ESCC | 5.17e-25 | 4.18e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00165754 | Esophagus | ESCC | histone deacetylation | 60/8552 | 82/18723 | 3.85e-07 | 5.32e-06 | 60 |
| GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| GO:00064764 | Oral cavity | OSCC | protein deacetylation | 66/7305 | 101/18723 | 7.36e-08 | 1.30e-06 | 66 |
| GO:00165753 | Oral cavity | OSCC | histone deacetylation | 54/7305 | 82/18723 | 7.68e-07 | 1.08e-05 | 54 |
| GO:003560113 | Oral cavity | LP | protein deacylation | 48/4623 | 112/18723 | 1.85e-05 | 3.14e-04 | 48 |
| GO:001657014 | Oral cavity | LP | histone modification | 152/4623 | 463/18723 | 4.04e-05 | 5.90e-04 | 152 |
| GO:001657511 | Oral cavity | LP | histone deacetylation | 37/4623 | 82/18723 | 4.28e-05 | 6.15e-04 | 37 |
| GO:009873212 | Oral cavity | LP | macromolecule deacylation | 48/4623 | 116/18723 | 5.51e-05 | 7.58e-04 | 48 |
| GO:000647613 | Oral cavity | LP | protein deacetylation | 41/4623 | 101/18723 | 3.03e-04 | 3.12e-03 | 41 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BRMS1L | SNV | Missense_Mutation | c.346N>T | p.Arg116Cys | p.R116C | Q5PSV4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| BRMS1L | SNV | Missense_Mutation | novel | c.603N>T | p.Lys201Asn | p.K201N | Q5PSV4 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRMS1L | SNV | Missense_Mutation | c.588N>G | p.Phe196Leu | p.F196L | Q5PSV4 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| BRMS1L | SNV | Missense_Mutation | novel | c.829N>A | p.Asp277Asn | p.D277N | Q5PSV4 | protein_coding | tolerated(0.39) | benign(0) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BRMS1L | SNV | Missense_Mutation | c.308T>C | p.Leu103Ser | p.L103S | Q5PSV4 | protein_coding | deleterious(0) | possibly_damaging(0.867) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BRMS1L | SNV | Missense_Mutation | novel | c.235C>G | p.Leu79Val | p.L79V | Q5PSV4 | protein_coding | deleterious(0.01) | probably_damaging(0.921) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BRMS1L | SNV | Missense_Mutation | novel | c.50N>C | p.Glu17Ala | p.E17A | Q5PSV4 | protein_coding | tolerated(0.09) | benign(0.031) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| BRMS1L | SNV | Missense_Mutation | novel | c.295G>T | p.Ala99Ser | p.A99S | Q5PSV4 | protein_coding | tolerated(0.14) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| BRMS1L | SNV | Missense_Mutation | novel | c.932C>T | p.Ser311Leu | p.S311L | Q5PSV4 | protein_coding | tolerated(0.08) | possibly_damaging(0.879) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| BRMS1L | SNV | Missense_Mutation | novel | c.373G>A | p.Glu125Lys | p.E125K | Q5PSV4 | protein_coding | tolerated(0.28) | possibly_damaging(0.74) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |